Markets open

argenx SE American Depositary Shares

ARGX · Nasdaq

Analyst Consensus

Buy

25 analysts

$870

Current

—

Low

$1,060

Average

—

High

Average target implies +21.80% versus the current price.

The ratings synthesis for ARGX has not been generated yet.

Rating Actions

No individual rating actions have been captured for ARGXyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

BAIRD R W

CITIGROUP

CITIZENS JMP

DEUTSCHE BK SEC

EVERCORE ISI

EXANE BNP PARIB

GUGGENHEIM SEC.

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

SCOTIABANK

SOCIETE GENERAL

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

UBS

WEDBUSH SECURIT

WELLS FARGO SEC

WILLIAM BLAIR

Symbol: ARGX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: Europe
Exchange: Nasdaq

argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.